Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 Plus Nab-paclitaxel and Cisplatin in First-line Advanced or Metastatic ESCC
NCT07533305Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Henan University of Science and Technology
- Start
- May 2026
- Primary completion
- Jun 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of QL1706 in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by First Affiliated Hospital of Henan University of Science and Technology. Planned start May 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07533305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07533305.